establishing the new standard for mr angiography€¦ · imaging (mri): omniscan, optiomark,...

2
©Toshiba Medical Systems Corporation 2007. All rights reserved. Design and specifications subject to change without notice. Made for Life and Vantage are trademarks of Toshiba Medical Systems Corporation. Model number: MRCSS1062US Establishing the new standard for MR Angiography Contrast without Contrast Foot-Notes: 1) Investigation of the safety of MRI contrast medium, Omniscan, May 29, 2006, Danish Medicines Agency Website. Available at: www.dkma.dk/1024/visUKLSArtikel.asp?artikelID=8931. 2) Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic system fibrosis? Nephrol Dial Transplant 2006; 21(4): 1104-1108 and erratum in 2006; 21(6): 1745. 3) Food and Drug Administration. Public health advisory: Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptioMARK, Magnevist, ProHance, and MultiHance. Available at: www.fda.gov/cder/drug/advisory/ gadolinium_agents.htm. Setting the new standard for state-of-the-art MR Vantage MR is powered by Toshiba’s exclusive Atlas technology featuring the world’s first 128 element RF coil design. Offering an array of features that boost image quality, patient care and productivity, Vantage lets you do more, better, and see things more clearly than ever. Increase patient safety with contrast-free exams that remove the requirement of administering agents along with the potential for gadolinium-induced toxicity. Enhance operational efficiency by eliminating the need to purchase contrast materials and reschedule failed exams because a second dose can’t be given immediately. Improve diagnostic capabilities with high resolution images that visualize slow flow areas more effectively by recording real blood vs. filling in gaps where contrast is excluded. Accelerate workflow and reduce technologist stress with light-weight coils and multi-element coils that don’t need to be removed and replaced to perform multiple procedures. Assure greater patient comfort with the industry’s quietest MR employing Pianissimo noise reduction technology, a larger gantry opening, and for the first time – feet-first imaging over 80% of the body. Expand image precision with a larger clinical FOV (55x55x50cm) that adds the ability to image larger patients more efficiently and effectively. Leading the way to safe MRA Based on a growing body of evidence that links gadolinium-based contrast agents with Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing Dermopathy (NSF/NFD), the Toshiba Vantage System offers the only alternative for performing rapid, ultra-clear MRA without using contrast agents. Along the way, it delivers high-quality diagnostic images, increased operational efficiency and across-the-board improvements in the quality of patient care. Patient Risk and Gadolinium NSF/NFD is a rare disease causing fibrosis of the skin and connective tissue throughout the body that has been associated with patients who had previously received gadolinium- based contrast agents. The first case of NSF/NSD was discovered in 1997 and it wasn’t until 2000 the disease showed up in medical literature. Subsequent to a 2006 press release from the Danish Medicines Agency 1 and a report by Grober 2 describing patients who developed the disease after undergoing these procedures, the FDA issued an alert urging caution with regard to the use of gadolinium-based contrast agents 3 . NSF/NFD is a progressive disease that can develop rapidly and often proves fatal. The underlying cause is not clearly understood and there is currently no consistently successful treatment or cure for NSF/NFD. Printed on recycled paper using soy inks

Upload: vuduong

Post on 12-Jun-2018

213 views

Category:

Documents


0 download

TRANSCRIPT

©Toshiba Medical Systems Corporation 2007. All rights reserved.Design and specifications subject to change without notice.Made for Life and Vantage are trademarks of Toshiba Medical Systems Corporation. Model number: MRCSS1062US

Establishing the new standard

for MR Angiography

Contrast without Contrast

Foot-Notes:

1) Investigation of the safety of MRI contrast medium, Omniscan,

May 29, 2006, Danish Medicines Agency Website. Available at:

www.dkma.dk/1024/visUKLSArtikel.asp?artikelID=8931.

2) Grobner T. Gadolinium – a specifi c trigger for the development

of nephrogenic fi brosing dermopathy and nephrogenic system

fi brosis? Nephrol Dial Transplant 2006; 21(4): 1104-1108 and

erratum in 2006; 21(6): 1745.

3) Food and Drug Administration. Public health advisory:

Gadolinium-containing contrast agents for magnetic resonance

imaging (MRI): Omniscan, OptioMARK, Magnevist, ProHance,

and MultiHance. Available at: www.fda.gov/cder/drug/advisory/

gadolinium_agents.htm.

Setting the new standard for state-of-the-art MR

Vantage MR is powered by Toshiba’s exclusive Atlas technology featuring

the world’s fi rst 128 element RF coil design. Offering an array of features

that boost image quality, patient care and productivity, Vantage lets you do

more, better, and see things more clearly than ever.

• Increase patient safety with contrast-free exams that remove the requirement of administering

agents along with the potential for gadolinium-induced toxicity.

• Enhance operational effi ciency by eliminating the need to purchase contrast materials and

reschedule failed exams because a second dose can’t be given immediately.

• Improve diagnostic capabilities with high resolution images that visualize slow fl ow areas more

effectively by recording real blood vs. fi lling in gaps where contrast is excluded.

• Accelerate workfl ow and reduce technologist stress with light-weight coils and multi-element

coils that don’t need to be removed and replaced to perform multiple procedures.

• Assure greater patient comfort with the industry’s quietest MR employing Pianissimo noise

reduction technology, a larger gantry opening, and for the fi rst time – feet-fi rst imaging over

80% of the body.

• Expand image precision with a larger clinical FOV (55x55x50cm) that adds the ability to image

larger patients more effi ciently and effectively.

Leading the way to safe MRA

Based on a growing body of evidence that links gadolinium-based contrast

agents with Nephrogenic Systemic Fibrosis/Nephrogenic Fibrosing

Dermopathy (NSF/NFD), the Toshiba Vantage System offers the only

alternative for performing rapid, ultra-clear MRA without using contrast agents.

Along the way, it delivers high-quality diagnostic images, increased operational

effi ciency and across-the-board improvements in the quality of patient care.

Patient Risk and Gadolinium

NSF/NFD is a rare disease causing fi brosis of the skin and connective tissue throughout

the body that has been associated with patients who had previously received gadolinium-

based contrast agents.

The fi rst case of NSF/NSD was discovered in 1997 and it wasn’t until 2000 the disease

showed up in medical literature.

Subsequent to a 2006 press release from the Danish Medicines Agency1 and a report

by Grober2 describing patients who developed the disease after undergoing these

procedures, the FDA issued an alert urging caution with regard to the use of

gadolinium-based contrast agents3.

NSF/NFD is a progressive disease that can develop rapidly and often proves fatal.

The underlying cause is not clearly understood and there is currently no consistently

successful treatment or cure for NSF/NFD.

Printed on recycled paper using soy inks

CIA : Contrast Improved AngiographyBuilding on Toshiba’s pioneering FBI technique, CIA represents newest-generation of contrast free development designed to provide easier acquisition of information and superior imaging of smaller vessels. Adding appropriate Flow Spoiler pulses to complete systolic black blood imaging reduces ghosting and improves arterial and venous flow separation. It also retains the advantages of reduced scan times and lack of issue sensitivity while expanding the window of opportunity for evaluating early disease states.

FBI of the lower extremities: Venous flow depicting varicose vein.

FBI of lower extremities: Arterial flow depicting popliteal artery trifurcation. CIA run-off.

Time-SLIP demonstrating the portal venous system.

Contrast-free techniques

In 1998, Toshiba pioneered non-contrast MR imaging and is the only imaging systems provider to offer a complete suite of contrast-free MRA techniques. Currently in their third generation of continuous development and improvement, Toshiba’s non-contrast imaging techniques include Fresh Blood Imaging (FBI), Contrast-Free Improved Angiography (CIA) and Time-Spatial Labeling Inversion Pulse (Time-SLIP). These techniques can be used to evaluate all non-neural vascular disease states and produce image quality that is as good as – or better than – images acquired using gadolinium-based agents.

FBI: Fresh Blood ImagingWith exceptional sensitivity to slow flow, FBI is particularly well-suited for evaluating peripheral vascular diseases of the lower extremities. Based on an ECG gated 3D FASE (Fast Advanced Spin Echo) technique, it acquires arterial and venous flow in a single coronal pass requiring less scan time than other MRA techniques. It also eliminates sensitivity to issues like improper timing, turbulent flow and differential filling that can cause contrast-based MRA to fail.

Time-SLIP: Spatial Labeling Inversion PulseTime-SLIP can be applied to many regions of the body and used for evaluating hemodynamic velocity functional assessments and visualization of vascular structures. Based on the Arterial Spin Labeling technique, it employs spatially, non-selective IR pulses and spatially selective tag pulses to reveal regions excited as bright or black blood and can be used with FASE or TRUE SSFP sequences in gated, two- and three-dimensional acquisitions.

Coronal and axial views of a Time-SLIP renal artery demonstrating the second and third order

branches without the use of contrast agents.

Time-SLIP of the renal artery after 3-D surface rendered post-processing with the Virtual Explorer workstation.

Whole body non-contrast CIA image.